You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Express Scripts
Dow
AstraZeneca
Johnson and Johnson
Harvard Business School
McKesson

Last Updated: July 12, 2020

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 210134


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

NDA 210134 describes BAQSIMI, which is a drug marketed by Eli Lilly And Co and is included in one NDA. It is available from one supplier. There are two patents protecting this drug. Additional details are available on the BAQSIMI profile page.

The generic ingredient in BAQSIMI is glucagon. There are twelve drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the glucagon profile page.
Summary for 210134
Tradename:BAQSIMI
Applicant:Eli Lilly And Co
Ingredient:glucagon
Patents:2
Formulation / Manufacturing:see details
Medical Subject Heading (MeSH) Categories for 210134
Suppliers and Packaging for NDA: 210134
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
BAQSIMI glucagon POWDER;NASAL 210134 NDA Eli Lilly and Company 0002-6145 0002-6145-11 1 TUBE in 1 CARTON (0002-6145-11) > 1 BOTTLE, UNIT-DOSE in 1 TUBE (0002-6145-02) > 1 POWDER in 1 BOTTLE, UNIT-DOSE (0002-6145-01)
BAQSIMI glucagon POWDER;NASAL 210134 NDA Eli Lilly and Company 0002-6145 0002-6145-27 2 TUBE in 1 CARTON (0002-6145-27) > 1 BOTTLE, UNIT-DOSE in 1 TUBE (0002-6145-02) > 1 POWDER in 1 BOTTLE, UNIT-DOSE (0002-6145-01)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:POWDER;NASALStrength3MG
Approval Date:Jul 24, 2019TE:RLD:Yes
Regulatory Exclusivity Expiration:Jul 24, 2022
Regulatory Exclusivity Use:NEW PRODUCT
Patent:  Start TrialPatent Expiration:Feb 16, 2036Product Flag?YSubstance Flag?Delist Request?
Patented Use:TREATMENT OF SEVERE HYPOGLYCEMIA IN PATIENTS WITH DIABETES
Patent:  Start TrialPatent Expiration:Jan 3, 2022Product Flag?YSubstance Flag?Delist Request?

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
AstraZeneca
Boehringer Ingelheim
Mallinckrodt
McKinsey
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.